Beigene Ltd (ADR)
General ticker "BGNE" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $20.3B
Beigene Ltd (ADR) follows the US Stock Market performance with the rate: 38.7%.
Estimated limits based on current volatility of 1.3%: low 173.85$, high 178.34$
Factors to consider:
- China accounted for 44.8% of revenue in the fiscal year ended 2023-12-31
- US accounted for 45.9% of revenue in the fiscal year ended 2023-12-31
- Price in estimated range
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [94.13$, 204.30$]
- 2024-12-30 to 2025-12-30 estimated range: [65.89$, 147.02$]
Financial Metrics affecting the BGNE estimates:
- Negative: Non-GAAP EPS, $ of -8.50 <= 0.10
- Negative: Operating profit margin, % of -32.94 <= 1.03
- Negative: Operating cash flow per share per price, % of -5.76 <= 2.35
- Negative: negative Net income
- Negative: Industry earnings per price (median), % of -26.04 <= 1.31
Short-term BGNE quotes
Long-term BGNE plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $1,176.28MM | $1,415.92MM | $2,458.78MM |
| Operating Expenses | $2,615.02MM | $3,205.59MM | $3,666.51MM |
| Operating Income | $-1,438.73MM | $-1,789.66MM | $-1,207.74MM |
| Non-Operating Income | $0.15MM | $-171.37MM | $381.90MM |
| Interest Expense | $0.00MM | $52.48MM | $0.00MM |
| R&D Expense | $1,459.24MM | $1,640.51MM | $1,778.59MM |
| Income(Loss) | $-1,438.59MM | $-1,961.04MM | $-825.84MM |
| Taxes | $19.23MM | $42.78MM | $55.87MM |
| Profit(Loss) | $-1,457.82MM | $-2,003.82MM | $-881.71MM |
| Stockholders Equity | $6,132.56MM | $4,383.35MM | $3,537.33MM |
| Inventory | $242.63MM | $282.35MM | $416.12MM |
| Assets | $8,535.52MM | $6,379.29MM | $5,805.27MM |
| Operating Cash Flow | $-1,298.72MM | $-1,496.62MM | $-1,157.45MM |
| Capital expenditure | $314.85MM | $469.10MM | $581.26MM |
| Investing Cash Flow | $640.66MM | $1,077.12MM | $60.00MM |
| Financing Cash Flow | $3,636.91MM | $-18.97MM | $416.48MM |
| Earnings Per Share* | $-15.23 | $-19.43 | $-8.45 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.